Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bisnorcymserine (Annovis Bio, Inc.)
- Development stage
- Unknown
- Lead developer
- Annovis Bio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bisnorcymserine (BNC) is a small molecule experimental drug developed by scientists at the National Institute on Aging (NIA) for the treatment of Alzheimer's disease. It belongs to the cymserine analog class and acts as a highly selective, reversible, and brain-specific inhibitor of butyrylcholinesterase (BChE). By blocking the BChE enzyme, bisnorcymserine aims to augment acetylcholine activity in the brain, addressing the cognitive and functional deficits associated with the loss of acetylcholine production in Alzheimer's patients. The drug has been evaluated in a Phase I first-in-human clinical trial to assess its safety, tolerability, and pharmacokinetics in healthy older volunteers.
- Other names
- bisnorcymserine tartrate
02
Targets
AcetylcholinesteraseButyrylcholinesterase
Beyond the preview
Go deeper on bisnorcymserine (Annovis Bio, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bisnorcymserine (Annovis Bio, Inc.).